Stockscreener 앱 받기
24.91
1.52%
0.305
전일 마감가:
$24.61
열려 있는:
$25.39
하루 거래량:
340.23K
Relative Volume:
0.25
시가총액:
$5.07B
수익:
-
순이익/손실:
$-464.20M
주가수익비율:
-9.2887
EPS:
-2.6823
순현금흐름:
$-423.09M
1주 성능:
-0.46%
1개월 성능:
-6.28%
6개월 성능:
+55.43%
1년 성능:
+87.72%
1일 변동 폭
$24.72
$25.62
1주일 범위
$23.24
$25.62
52주 변동 폭
$12.72
$29.25
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-410-3120
주소
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
24.91 | 5.01B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
441.31 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
774.76 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
784.60 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
326.68 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.47 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Mkt Perform |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
IMVT Shares Drop 2.4% After Batoclimab Fails to Meet Key Goals in Final-Stage Trial - bitget.com
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - Yahoo Finance
Immunovant falls on late-stage trial setback for TED therapy - MSN
Immunovant Inc stock: Why biotech investors are watching this closely now - AD HOC NEWS
Aberdeen Group plc Increases Stake in Immunovant, Inc. $IMVT - MarketBeat
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Immunovant (NASDAQ:IMVT) CEO Sells $342,918.90 in Stock - MarketBeat
Immunovant (IMVT) CEO Venker sells $342,854 in shares By Investing.com - Investing.com India
Immunovant (IMVT) CEO Venker sells $342,854 in shares - Investing.com
Immunovant (IMVT) CEO settles CVARs into 368,750 shares, disposes stock - Stock Titan
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
IMVT Should I Buy - intellectia.ai
Truist reiterates Hold on Immunovant stock after trial failure By Investing.com - Investing.com India
Immunovant's treatment for eye disease fails in late-stage trials - Reuters
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data UpdateSlideshow - Seeking Alpha
IMVT: Brepocitinib advances into pivotal LPP trials as batoclimab's TED study informs Graves' strategy - TradingView
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP - Yahoo Finance
Leerink cuts Immunovant stock price target on failed TED trial By Investing.com - Investing.com Australia
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM - BioPharma Dive
Leerink cuts Immunovant stock price target on failed TED trial - Investing.com
Oppenheimer maintains Immunovant stock rating on next-gen drug focus By Investing.com - Investing.com India
Oppenheimer maintains Immunovant stock rating on next-gen drug focus - Investing.com UK
IMVT: Batoclimab missed its Phase 3 endpoint in thyroid eye disease; focus shifts to IMVT-1402 - tradingview.com
Roivant Shrugs Off Batoclimab Phase III Failure in TED - Citeline News & Insights
Immunovant’s batoclimab fails Phase 3 thyroid eye disease trials By Investing.com - Investing.com Canada
Hennion & Walsh Asset Management Inc. Makes New Investment in Immunovant, Inc. $IMVT - MarketBeat
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) - manilatimes.net
Immunovant’s batoclimab fails Phase 3 thyroid eye disease trials - Investing.com
Two late-stage thyroid eye disease trials miss for Immunovant - Stock Titan
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results - MSN
Sjögren’s Syndrome Market Poised for Significant Expansion Through 2034, Driven by Advancing Pipeline Therapies and Rising Disease Burden | DelveInsight Analysis Featuring Astellas Pharma, Immunovant - Barchart
Responsive Playbooks and the IMVT Inflection - Stock Traders Daily
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish - AOL.com
EPS Watch: Does PCOR have consistent dividend growthExit Point & Fast Moving Stock Watchlists - baoquankhu1.vn
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? - AOL.com
Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock - Investing.com India
Top Immunovant Executive Quietly Cashes Out in Notable Insider Stock Move - TipRanks
Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 2,877 Shares - MarketBeat
Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock By Investing.com - za.investing.com
Immunovant, Inc. (IMVT) CLO sells 2,877 shares to cover RSU taxes - Stock Titan
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.27%
1.21%
자본화:
|
볼륨(24시간):